Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
On November 22, 2022, Dr. Reddy's
Laboratories Ltd. informed that it and Dr. Reddy's Laboratories, Inc. (a wholly owned subsidiary of the Company) had been
named as defendants, along with Celgene, Bristol Myers Squibb, and several other generic pharmaceutical companies, in a complaint
that asserts claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition
and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States. On December 22, 2022 and
December 27, 2022, the plaintiffs voluntarily dismissed Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories,
Inc., respectively, from the case. All claims against the Company in the litigation have now been dismissed.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary, Compliance Officer and Head CSR |
NSE IFSC Ltd. (Stock Code: